Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2025-12-31 @ 1:04 AM
Study NCT ID:
NCT01832467
Status:
COMPLETED
Last Update Posted:
2020-06-18
First Post:
2013-04-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cetuximab Rechallenge Study
Sponsor:
Chinese University of Hong Kong
Organization:
Study Overview
Official Title:
A Pilot Case-control Study of Second or Third Line Treatment With Cetuximab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer Who Were Previously Treated With Cetuximab-based Chemotherapy
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the objective overall response of re-treatment with cetuximab-based chemotherapy in patients upon disease progression while under observation, who had previously responded to first-line or second-line treatment with cetuximab-based chemotherapy for metastatic colorectal cancer (mCRC), but had stopped treatment for reasons other than disease progression.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: